1. Home
  2. BBNX vs MNMD Comparison

BBNX vs MNMD Comparison

Compare BBNX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$31.13

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$13.47

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
MNMD
Founded
2015
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
BBNX
MNMD
Price
$31.13
$13.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
9
Target Price
$28.92
$30.33
AVG Volume (30 Days)
928.2K
2.1M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,570,000.00
N/A
Revenue This Year
$52.13
N/A
Revenue Next Year
$36.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
67.01
N/A
52 Week Low
$8.89
$4.70
52 Week High
$32.71
$14.81

Technical Indicators

Market Signals
Indicator
BBNX
MNMD
Relative Strength Index (RSI) 55.06 56.37
Support Level $28.36 $12.85
Resistance Level $32.21 $14.81
Average True Range (ATR) 1.66 0.76
MACD -0.18 0.03
Stochastic Oscillator 66.89 49.82

Price Performance

Historical Comparison
BBNX
MNMD

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: